Loading…
Loading…
Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company's stock, valued at approximately $476,000. Other large investors have also
BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company's stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the
Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company's stock after purchasing an additional 39,571 shares
Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company's stock, valued at approximately $623,000. Bank of Nova Scotia owned about
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.
Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript